Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Submitted by admin on August 3, 2018 - 9:25am
Source: 
CP Wire
News Tags: 
AstraZeneca
Merck
selumetinib
Array Biopharma
orphan drugs
NF1
neurofibromatosis
Headline: 
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
snippet: 
  • Selumetinib granted Orphan Status by the FDA in 2018
  • NF1 gene mutation occurs in approximately one in 3,000 births
  • Array Biopharma claims AZ owes approximately $192 million in unpaid royalty fees related to selumetinib agreement

Do Not Allow Advertisers to Use My Personal information